You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 24, 2024

Infigratinib phosphate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic drug sources for infigratinib phosphate and what is the scope of patent protection?

Infigratinib phosphate is the generic ingredient in one branded drug marketed by Helsinn Hlthcare and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Infigratinib phosphate has one hundred and thirty-five patent family members in forty countries.

Summary for infigratinib phosphate
International Patents:135
US Patents:4
Tradenames:1
Applicants:1
NDAs:1
Raw Ingredient (Bulk) Api Vendors: 33
Clinical Trials: 1
Patent Applications: 26
DailyMed Link:infigratinib phosphate at DailyMed
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for infigratinib phosphate
Generic Entry Date for infigratinib phosphate*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for infigratinib phosphate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Emory UniversityPhase 2
National Cancer Institute (NCI)Phase 2

See all infigratinib phosphate clinical trials

US Patents and Regulatory Information for infigratinib phosphate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Helsinn Hlthcare TRUSELTIQ infigratinib phosphate CAPSULE;ORAL 214622-001 May 28, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Helsinn Hlthcare TRUSELTIQ infigratinib phosphate CAPSULE;ORAL 214622-001 May 28, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Helsinn Hlthcare TRUSELTIQ infigratinib phosphate CAPSULE;ORAL 214622-001 May 28, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Helsinn Hlthcare TRUSELTIQ infigratinib phosphate CAPSULE;ORAL 214622-002 May 28, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Helsinn Hlthcare TRUSELTIQ infigratinib phosphate CAPSULE;ORAL 214622-001 May 28, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up Y ⤷  Sign Up
Helsinn Hlthcare TRUSELTIQ infigratinib phosphate CAPSULE;ORAL 214622-001 May 28, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Helsinn Hlthcare TRUSELTIQ infigratinib phosphate CAPSULE;ORAL 214622-002 May 28, 2021 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

International Patents for infigratinib phosphate

Country Patent Number Title Estimated Expiration
European Patent Office 3079667 FORMES PHARMACEUTIQUES (PHARMACEUTICAL DOSAGE FORMS) ⤷  Sign Up
Slovenia 2509963 ⤷  Sign Up
China 111100077 3-(2,6-二氯-3,5-二甲氧基-苯基)-1-{6-[4-(4-乙基-哌嗪-1-基)-苯基氨基]-嘧啶-4-基}-1-甲基-脲及其盐的晶型 (Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl) -1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino] -pyrimidin-4-yl}-1-methyl-urea and salts thereof.) ⤷  Sign Up
Tunisia 2012000263 CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF. ⤷  Sign Up
Mexico 2016007652 FORMAS DE DOSIFICACION FARMACEUTICAS. (PHARMACEUTICAL DOSAGE FORMS.) ⤷  Sign Up
Argentina 050343 DERIVADOS DE PIRIMIDIN-UREA ⤷  Sign Up
Israel 220012 צורות קריסטליות של 3-(6,2-דיכלורו-5,3-דימתוקסי-פניל)-1-{6-[4-(4-אתיל-פיפרזינ-1-יל)-פנילאמינו]-פירימידינ-4-יל}-1-מתיל-אוריאה ומלחים שלו (Crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea and salts thereof) ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.